ABSTRACTS
P.12 PRIMARY OVARIAN CARCINOMA: AN UNUSUAL EXTRA-MAMMARY TUMOR METASTASIZING TO THE BREAST: A RETROSPECTIVE ANALYSIS
G. El Hachem, L. Polastro, J. Kerger
P.03 THE TRITON CLINICAL TRIAL PROGRAMME: EVALUATION OF THE POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITOR RUCAPARIB IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) ASSOCIATED WITH HOMOLOGOUS RECOMBINATION DEFICIENCY
B. Sautois, J.C. Goeminne, S. Rottey, D. Schrijvers, F. Van Aelst, S. Van Bruwaene, S. Watkins, A. Simmons, Jowell Go, Melanie Collins, T. Golsorkhi, W. Abida, C. Ryan, Howard Scher, S. Chowdhury
P.04 ENDOTHELIAL CELL METABOLISM BLOCKADE TO INDUCE TUMOR VESSEL NORMALIZATION AND IMPROVE CURRENT IMMUNOTHERAPY
V. Geldhof, A.R. Cantelmo, Peter Carmeliet
P.05 LONG-TERM CLINICAL OUTCOME AND SURVIVORSHIP ISSUES OF HIGH GRADE BONE SARCOMAS
C. Closset, T. Gil, Martine Piccart
P.06 THE IMPACT OF NETWERK ON THE MULTIDISCIPLINARY TUMOR BOARDS
T. Vandamme, W. Lybaert, Marc Simoens, Wim Demey, T. Rondou, P. Abrams, C. Mattelaer, B. Op de Beeck, O. D’Archambeau, G. Roeyen, Lesley De Backer, Marc Peeters, Steering Committee, NET-specialists
P.07 EXCELLENT SURVIVAL OUTCOMES FOR NET PATIENTS TREATED WITHIN NETWERK, A COLLABORATIVE ENETS CENTER OF EXCELLENCE
T. Vandamme, Isabelle Maurissen, W. Lybaert, Marc Simoens, P. Abrams, A. Driessen, B. Op de Beeck, Wim Demey, T. Rondou, M. Ulenaers, G. Vanhoutte, Marc Peeters, Steering Committee, NET-specialists
P.08 AUTOIMMUNE POLYARTHRITIS: A RARE COMPLICATION OF RENAL CLEAR CELL CARCINOMA ON IMMUNOTHERAPY
X. Wang, Georges El Hachem, W. Bekolo, Lissandra Dal Lago, A. Georgala, T. Pepersack, S. Aspeslagh, Laurence Buisseret, T. Gil, A. Awada
P.09 BRAIN METASTASIS: AN UNUSUAL DISSEMINATION OF EXTRA-OSSEOUS EWING SARCOMA
G. El Hachem, C. Jungels
P.10 PRECLINICAL CDK4/6 INHIBITION FOR SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
G. Van Caloen
P.11 A-146 LONG TERM RESPONSE WITH COMBINATION IMMUNOTHERAPY IN A PATIENT WITH SYMPTOMATIC MELANOMA BRAIN METASTASES
T. Wessels, J. Mebis
P.02 THE ROLE OF TOPOISOMERASE II-A (TOPO IIA) AS A PREDICTIVE FACTOR FOR RESPONSE TO NEOADJUVANT ANTHRACYCLINES BASED CHEMOTHERAPY IN LOCALLY ADVANCED BREAST CANCER
Mohamed Gamea
P.13 UNEXPECTED TOXICITY IN A PATIENT TREATED WITH FLUOROPYRIMIDINES FOR A METASTATIC BREAST CANCER
Y. Wissam, C. Hanssens, Y. Lalami, A. Georgala, A. Awada
P.14 METASTATIC MELANOMA: CURED BY SURGERY OR DELAYED IMMUNOTHERAPY RESPONSE
E. Roets, Karina Tukanova, A. Govarts, P. Specenier
P.15 ABOUT A COMBINATION OF LOWER ESOPHAGEAL CANCER AND SECONDARY CEREBRAL LOCALIZATION
F. Djema, A. Awada
P.16 ABOUT A CASE: MALE BREAST CANCER WITH PULMONARY METASTASES AND THERAPEUTIC RESPONSE TO EVEROLIMUS+EXEMESTANE
F. Djema, A. Awada
P.17 PROGRAMMED CELL DEATH-1 (PD-1) INHIBITORS: DON’T FORGET TYPE 1 DIABETES MELLITUS! A CASE REPORT
Katleen Janssens, Katrien Clotman, P. Specenier, C. De Block
P.18 QUALITY OF LIFE, FATIGUE, AND SUBJECTIVE COGNITIVE FUNCTIONING IMMEDIATELY AND 6 MONTHS AFTER ADJUVANT CHEMOTHERAPY IN BREAST CANCER PATIENTS
J. Mebis, S. Censabella, S. Engels, C. Van Narsenille, Guy Orye, S. Marquette, L. Vansteelant, L. Noé, A. Maes, P. Bulens, D. Luyten, E. Joosens
P.19 A-105 WHEN DRUG TOXICITIES ARE DRIVEN BY SOCIAL HABITS: A CASE REPORT
Y. Jounblat, G. El Hachem, A. Drowart, J. Kerger
P.10 PULMONARY SARCOID-LIKE GRANULOMATOSIS INDUCED BY PEMBROLIZUMAB IN A PATIENT WITH MELANOMA
Ionela Bold, J. Kerger, B. Grigoriu
O.03 DETECTION OF AR PERTURBATIONS IN CIRCULATING TUMOUR CELLS AND CELL-FREE DNA FROM PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PREDICTS RESISTANCE TO ENDOCRINE THERAPY
B. De Laere, Markus Mayrhofer, T. Whitington, P-J. Van Dam, P. Van Oyen, C. Ghysel, J. Ampe, P. Ost, Wim Demey, L. Hoekx, D. Schrijvers, B. Brouwers, W. Lybaert, E. Everaert, P. Van Kerckhove, D. De Maeseneer, M. Strijbos, A. Bols, K. Fransis, Nick Beije, Inge De Kruijff, S. Oeyen, A. Rutten, V. Van Dam, A. Brouwer, D. Goossens, Lien Heyrman, G. Van Den Eynden, J. Vandebroek, Jurgen Del-Favero, S. Sleijfer, A. Uhlen, Jeffrey Yachnin, S. Van Laere, Henrik Grönberg, Johan Lindberg, L. Dirix
O.01 IDENTIFICATION, CLINICAL CHARACTERISTICS AND TREATMENT OUTCOMES OF SOMATIC HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) MUTATIONS IN METASTATIC BREAST CANCER PATIENTS
L. Jongen, Giuseppe Floris, D. Lambrechts, Annouschka Laenen, Patrick Neven, Grace Mann, Richard Cutler Jr., A. Lalani, H. Wildiers
O.02 REAL-LIFE TREATMENT PRACTICE FOR MALIGNANT PLEURAL MESOTHELIOMA IN BELGIUM
Michael Rosskamp, Gilles Macq, Kristiaan Nackaerts, Marleen Praet, L. Van Eycken, Jan Van Meerbeeck, Harlinde De Schutter
O.04 PLOCABULIN, A TUBULIN INHIBITOR, HAS ANTITUMOR ACTIVITY IN PATIENT-DERIVED XENOGRAFT (PDX) MODELS OF GASTROINTESTINAL STROMAL TUMOR (GIST)
Y. Wang, A. Wozniak, Jasmien Wellens, Y. Gebreyohannes, Maria Jose Guillén, C.M. Galmarini, Pablo M. Avilés, Maria Debiec-Rychter, Raf Sciot, Patrick Schöffski
O.05 MT4-MMP, EGFR AND RB EXPRESSIONS ARE PREDICTIVE BIOMARKERS OF RESPONSE TO ERLOTINIB-PALBOCICLIB COMBINATION IN TRIPLE NEGATIVE BREAST CANCERS
Pierre Foidart, Nor-Eddine Sounni, G. Jerusalem
O.06 PHOTOBIOMODULATION THERAPY FOR THE PREVENTION OF ACUTE RADIATION DERMATITIS: PRELIMINARY RESULTS OF A RANDOMIZED, PLACEBO-CONTROLLED TRIAL IN BREAST CANCER PATIENTS
J. Robijns, S. Censabella, S. Claes, Luc Pannekoeke, Lore Bussé, D. Colson, Iris Kaminski, A. Maes, P. Bulens, M. Brosens, L. Noé, Ivo Lambrichts, A. Timmermans, V. Somers, J. Mebis
O.07 EFFECT OF MINDFULNESS TRAINING ON QUALITY OF LIFE AND DISTRESS IN CANCER PATIENTS
J. Mebis, S. Censabella, S. Engels, Guy Orye, S. Marquette, C. Van Narsenille, L. Vansteelant, L. Noé, A. Maes, P. Bulens, D. Luyten, E. Joosens
O.08 ULTRA-DEEP TARGETED RESEQUENCING REVEALS RECURRENT DAXX AND CYFIP2 MUTATIONS AND IMPLICATES NOVEL PATHWAYS IN PANCREATIC NEUROENDOCRINE TUMORS
T. Vandamme, Matthias Beyens, Guy Van Camp, Gitta Boons, Leo Hofland, Marc Peeters, Ken Op de Beeck
O.09 GLIOBLASTOMA MULTIFORME (GBM): STUPP AND REALITY
N. van den Eede, P. Specenier, A. de Paepe
O.10 THE DEUBIQUITINASE USP13 AS A NOVEL THERAPEUTIC CO-TARGET IN EGFR MUTANT NON-SMALL CELL LUNG CANCER
P. Giron, C. Eggermont, E. Teugels, G. Gutierrez, J. De Grève
P.01 A LUNG CANCER-DERIVED CRAF MUTATION IS ERK PATHWAY ACTIVATING AND PREDICTS SENSITIVITY TO COMBINED TYPE II RAF AND MEK INHIBITION
A. Noeparast, J. De Grève, S. De Brakeleer, P. Giron, C. Eggermont, Rajendra Bahadur Shahi, E. Teugels
Top
